Tianjin Chase Sun Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Tianjin Chase Sun Pharmaceutical Co Ltd cash flow-to-debt ratio. Tianjin Chase Sun Pharmaceutical Co Ltd (300026) has a Cash Flow-to-Debt Ratio of 0.08x as of September 2025, meaning its operating cash flow of CN¥153.30 Million could theoretically repay 0% of its total liabilities (CN¥1.96 Billion) in one year. Check 300026 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Tianjin Chase Sun Pharmaceutical Co Ltd (2006–2024)
Cash flow-to-debt ratio of Tianjin Chase Sun Pharmaceutical Co Ltd from 2006 to 2024. Historical debt coverage capacity for Tianjin Chase Sun Pharmaceutical Co Ltd across 19 annual periods. Check total reinvestment intensity of Tianjin Chase Sun Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Tianjin Chase Sun Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2006–2024)
Tianjin Chase Sun Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2006 to 2024. Year-by-year debt coverage analysis for Tianjin Chase Sun Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Tianjin Chase Sun Pharmaceutical Co Ltd cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.36x | CN¥852.24 Million | CN¥2.37 Billion | ▼ -30.2% |
| 2023 | 0.52x | CN¥1.53 Billion | CN¥2.97 Billion | ▲ +188.3% |
| 2022 | 0.18x | CN¥745.35 Million | CN¥4.17 Billion | ▲ +66.9% |
| 2021 | 0.11x | CN¥391.60 Million | CN¥3.65 Billion | ▲ +51.9% |
| 2020 | 0.07x | CN¥196.66 Million | CN¥2.79 Billion | ▼ -55.7% |
| 2019 | 0.16x | CN¥216.10 Million | CN¥1.36 Billion | ▼ -62.7% |
| 2018 | 0.43x | CN¥388.19 Million | CN¥907.61 Million | ▼ -47.0% |
| 2017 | 0.81x | CN¥742.38 Million | CN¥919.62 Million | ▲ +123.9% |
| 2016 | 0.36x | CN¥448.08 Million | CN¥1.24 Billion | ▲ +252.5% |
| 2015 | 0.10x | CN¥121.00 Million | CN¥1.18 Billion | ▼ -53.3% |
| 2014 | 0.22x | CN¥149.94 Million | CN¥684.85 Million | ▼ -21.3% |
| 2013 | 0.28x | CN¥143.60 Million | CN¥516.40 Million | ▼ -24.1% |
| 2012 | 0.37x | CN¥152.21 Million | CN¥415.19 Million | ▲ +267.7% |
| 2011 | 0.10x | CN¥35.64 Million | CN¥357.47 Million | ▼ -60.7% |
| 2010 | 0.25x | CN¥46.25 Million | CN¥182.14 Million | ▼ -74.6% |
| 2009 | 1.00x | CN¥135.06 Million | CN¥134.90 Million | ▲ +18.0% |
| 2008 | 0.85x | CN¥77.74 Million | CN¥91.63 Million | ▲ +34.1% |
| 2007 | 0.63x | CN¥72.01 Million | CN¥113.79 Million | ▲ +4259.8% |
| 2006 | 0.01x | CN¥1.22 Million | CN¥84.34 Million | — |